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Abstract
The final outcome of infection by Trypanosoma brucei gambiense, the main agent of sleeping sickness, has always been
considered as invariably fatal. While scarce and old reports have mentioned cases of self-cure in untreated patients, these
studies suffered from the lack of accurate diagnostic tools available at that time. Here, using the most specific and sensitive
tools available to date, we report on a long-term follow-up (15 years) of a cohort of 50 human African trypanosomiasis (HAT)
patients from the Ivory Coast among whom 11 refused treatment after their initial diagnosis. In 10 out of 11 subjects who
continued to refuse treatment despite repeated visits, parasite clearance was observed using both microscopy and
polymerase chain reaction (PCR). Most of these subjects (7/10) also displayed decreasing serological responses, becoming
progressively negative to trypanosome variable antigens (LiTat 1.3, 1.5 and 1.6). Hence, in addition to the ‘‘classic’’ lethal
outcome of HAT, we show that alternative natural progressions of HAT may occur: progression to an apparently
aparasitaemic and asymptomatic infection associated with strong long-lasting serological responses and progression to an
apparently spontaneous resolution of infection (with negative results in parasitological tests and PCR) associated with a
progressive drop in antibody titres as observed in treated cases. While this study does not precisely estimate the frequency
of the alternative courses for this infection, it is noteworthy that in the field national control programs encounter a
significant proportion of subjects displaying positive serologic test results but negative results in parasitological testing.
These findings demonstrate that a number of these subjects display such infection courses. From our point of view,
recognising that trypanotolerance exists in humans, as is now widely accepted for animals, is a major step forward for future
research in the field of HAT.
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Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by infection of two trypanosome sub-species transmitted by
tsetse flies, Trypanosoma brucei (T.b.) gambiense and T.b. rhodesiense,
with T.b. gambiense causing more than 95% of all cases [1]. The
disease evolves from an early haemolymphatic phase (first stage,
P1) to a meningoencephalitic phase (second stage, P2) when the
parasites invade the central nervous system leading to neurological
disorders [2]. Whereas some T.b. gambiense patients develop a
chronic disease (i.e. remaining in stage 1 for several years), others
progress more rapidly to stage 2 within several months [3]. In the
absence of treatment, HAT is widely assumed to be 100% fatal.
Indeed, HAT probably killed more than one million people over
the three major epidemics that ravaged the African continent
during the twentieth century [2,4].
Little is known about T.b. gambiense infection outcome in the
absence of treatment, because usually HAT patients are system-
atically treated as soon as possible after diagnosis, even in the
absence of clinical symptoms, since the disease is potentially fatal
and tsetse flies can be infected by feeding on these patients [5].
Although reports on asymptomatic carriers and spontaneous cure
have been published, questions on the existence of human
trypanotolerance still remain [6,7,8,9]. Among the few recently
published studies is the example of 53 HAT patients diagnosed in
the Sinfra focus (western central part of the Ivory Coast) in 1995–
1996 but refusing treatment. These patients were re-examined
several times between 1997 and 1999 in order to convince them to
accept treatment [10]. Twenty-nine patients accepted treatment,
mainly because of the progressive appearance of neurological
disorders. Two patients still refused treatment despite the onset of
neurological signs and eventually died. Such courses can be
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considered as the ‘‘classic’’ fatal progression of HAT. In 1999,
among 15 patients who remained untreated, six were still
parasitologically positive with only one showing neurological
signs. Interestingly, in nine patients, an apparent parasitological
clearance was observed, among whom six still had positive
results on the card agglutination test for trypanosomiasis
(CATT) [11] and three had negative CATT results. Of these
patients refusing treatment, three of the six patients who were
still parasitologically positive and three of the six still CATT-
positive but parasitologically negative in 1999 were re-examined
in 2002. All were parasite-negative by microscopy, but PCR-
positive [12], suggesting that these individuals carried latent
infections.
During surveillance activities in 2004 and 2009, the above-
mentioned untreated patients as well as treated HAT patients from
the same Sinfra focus who were diagnosed within the same period
(1995–1996) were re-visited to assess their parasitological and
serological status. In addition, we included other HAT cases
diagnosed between 2000 and 2007 in the nearby Bonon focus
[13,14], as we had learnt from the local health authorities that they
had not yet been treated. We report here on the data obtained
throughout this long-term follow-up period.
Our results, based on clinical, serological, molecular, and
parasitological investigations, combining field diagnostic tools and
highly specific and sensitive laboratory tests, constitute the most
comprehensive study on the natural evolution of Trypanosoma brucei
gambiense infection in its human host. At least two alternative




All samples were collected within the framework of medical
surveys and epidemiological surveillance activities supervised by
the national HAT control program (NCP). No samples other than
those collected for routine screening and diagnostic procedures
were collected. All participants were informed about the objective
of the study in their own language and signed an informed consent
form. This study is part of a larger project aiming at improving
HAT diagnosis for which approval was obtained from the WHO
(Research Ethics Review Committee) and Institut de Recherche
pour le De´veloppement (Comite´ Consultatif de De´ontologie et
d’Ethique) ethical committees.
Study subjects
Within the framework of surveillance activities carried
out in February 2004 and May 2009 in the western central
part of the Ivory Coast in collaboration with the National
Control Program (NCP) and local health structures, the
following 50 subjects were re-examined to assess the progression
of their HAT status:
N HAT patients diagnosed between 1995 and 1996 in the Sinfra
focus who had not been treated after initial diagnosis (n=7)
N HAT patients diagnosed between 2000 and 2007 in the Bonon
focus who had not been treated after initial diagnosis (n=4)
N HAT patients diagnosed (18 in first stage, 21 in second stage)
between 1995 and 1996 in the Sinfra focus (n=39) who
received treatment after initial diagnosis
Diagnostic tests and clinical examination
Blood (4 ml) was collected in heparinised tubes. A twofold
plasma dilution series made in CATT buffer was tested to assess
the end titre, i.e. the highest dilution still positive (CATT-P).
CATT-P was considered positive if the end titre $1/8. CATT is
the main serological test used for mass-screening in T. b.
gambiense endemic areas. All subjects included in the study
underwent parasitological examinations by the mini-anion
exchange centrifugation technique [15] and by direct micro-
scopical examination of lymph node aspirate when enlarged
lymph nodes were present.
As the CATT is known to exhibit false-positive results, Immune
trypanolysis tests (TL) were performed on plasma as previously
described [16] with LiTat 1.3, 1.5 and 1.6 variable antigen types
(VAT) of T. b. gambiense. The TL test is highly specific for T. b.
gambiense and is now routinely used in West Africa in the frame of
epidemiological surveillance to better characterise parasitologically
unconfirmed CATT-seropositive subjects [17]. Polymerase chain
reaction (PCR) using the TBR1/TBR2 primers specific for
Trypanozoon [18] was performed on DNA extracted from 500 ml
of whole blood [19].
For all study subjects, a clinical form was filled out, recording
symptoms such as fever, headache, loss of appetite, asthenia,
presence of swollen cervical lymph nodes or the following
neurological symptoms: daytime somnolence or nocturnal insom-
nia, presence of the palmomental reflex, sexual activity distur-
bance, abnormal movements such as tremors and psychiatric




No neurological disorders specific of the meningoencephalitic
stage of the disease were observed in any of the examined subjects.
Non-specific clinical signs, such as fever and headache, were
frequently reported, in 58% of the treated and 68% of the non-
treated study subjects, but the difference was not significant.
Enlarged cervical lymph nodes were detected only in one
untreated patient from the Bonon focus.
Author Summary
The existence of a diversity of infection outcomes –
ranging from self-cure to asymptomatic, severe or fatal
cases – is now widely recognised for most parasitic and
infectious diseases. The dogma concerning sleeping
sickness, however, is still that infection is 100% fatal. Here
we describe a 15-year follow-up of patients diagnosed
with human African trypanosomiasis (HAT) in the Ivory
Coast but who refused treatment. Our results, based on
clinical, serological, molecular, and parasitological investi-
gations, combining diagnostic tools for the field and highly
specific and sensitive laboratory tests, constitute the most
comprehensive study on the natural evolution of Trypano-
soma brucei gambiense infection in its human host. At least
two alternative natural progressions of HAT to the ‘‘classic’’
fatal disease were identified: a progression to an appar-
ently aparasitaemic and asymptomatic infection and a
progression to an apparently spontaneous resolution of
infection. We believe that recognising that trypanotoler-
ance exists in humans is a major step forward for future
research aimed at identifying human-specific defence and
immune mechanisms involved in the control of T.b.
gambiense infection and thus new candidate therapeutic
or prophylactic targets.
Self-Cure and Latent Infections in HAT
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Serological and parasitological status of treated HAT
patients 15 years after diagnosis
In the Sinfra focus, 39 HAT patients diagnosed (CATT on
plasma (CATT-P) and parasitologically positive) and treated in
1995–1996 (HAT-treated) were examined in 2009. All had
negative results in both parasitological and PCR tests. Results of
the CATT-P and trypanolysis test (TL) are given in Table 1.
Fourteen (35.9%) patients showed negative results in both CATT
and TL tests. Three patients (7.7%) still had positive CATT-P
results, while 24 (61.5%) had positive TL results, of which only two
were positive for all three variable antigen types (VATs). More
stage 2 (P2) HAT-treated patients had positive TL results (17/21,
81%) than stage 1 (P1) HAT-treated patients (7/18, 38.9%),
although this difference was not significant (p=0.19, Fisher exact
test).
Serological and parasitological status in HAT patients
refusing treatment
In the Sinfra focus, seven individuals recorded as subjects 4, 5,
6, 7, 12, 13, and 14 by Jamonneau et al., 2000 [10], still living in
the area and never treated for HAT, were re-examined in 2004
and 2009. Parasitological, serological, and PCR results obtained in
1999 [10], 2004, and 2009 are given in Table 2. While
trypanosomes were detected in three of these seven patients in
1999, none of them was found to have the parasite by microscopy
in 2004 and 2009. While all patients examined in 1999 and 2004
were PCR-positive, they were all PCR-negative in 2009. Three
patients had CATT-P positive results in 2009 and six had TL-
positive results with two or three VATs. Patient 4 had negative
results for all tests in 2009. Patients 5, 6 and 14 became CATT-P-
negative but were still TL-positive in 2009. Patients 7, 12 and 13
remained CATT-P-positive and were TL-positive with the three
VATs tested in 2009.
In the Bonon focus, four untreated HAT patients diagnosed
between 2000 and 2007 and still living in the area were re-
examined in 2009. Results are shown in Table 3. One patient
(BONT4) still had positive microscopy results for both lymph and
blood samples tested in 2009. He also had positive results on the
CATT-P and TL tests with the three VATs and PCR. The patient
continued to refuse to go to the treatment centre where lumbar
punctures are performed before initiating treatment. It was
therefore not possible to determine the disease stage, although
clinical investigations suggest that he was likely still in the first
stage. The other three patients diagnosed before 2005 had
negative results in both CATT-P and parasitological tests. These
three patients were TL-positive with LiTat 1.3 and LiTat 1.6, but
negative with LiTat 1.5.
Discussion
The identification and follow-up over 5–15 years of 11 patients
diagnosed with HAT in the Ivory Coast but refusing treatment
was a unique opportunity to characterise the diversity of T. b.
gambiense infection outcomes in its human host. The data presented
here – based on clinical, serological, molecular and parasitological
investigations, combining field diagnostic tools (mAECT and
CATT) and more specific and sensitive laboratory tests (TL and
PCR) – challenge the dogma that T.b. gambiense infection in
humans is 100% fatal.
Clinical and parasitological cure is associated with a
progressive decrease of the serological response
All patients re-examined 15 years after treatment were clinically
healthy and parasitologically negative to both mAECT and PCR.
Whilst most patients became CATT-P-negative, 61.5% remained
TL-positive. This result confirms that T.b. gambiense-specific
antibodies may remain present in blood for several years after
successful treatment [20,21,22,23] and that TL is more sensitive in
detecting these antibodies. However, in contrast to what is
observed during active disease in which TL reactivity to all three
VATs is systematically seen in the Ivory Coast [17], almost all TL-
positive treated patients were negative to at least one VAT.
Serologically, cure is associated with a decrease of CATT positivity
and a progressive loss of reactivity to the different VATs, a process
that can last for years.
Since these apparently cured patients had parasitologically
negative blood test results, and since there was no clinical suspicion
of relapse, for ethical reasons no lumbar puncture was performed
to check for the presence of trypanosomes and/or abnormal white
cell counts in the cerebrospinal fluid (CSF). We therefore cannot
exclude that there were trypanosomes in the CSF, hidden from the
peripheral immune system. In this regard, a recent large-scale
study carried out in the Democratic Republic of the Congo has
shown that in contrast to PCR on blood, PCR on CSF can
sometimes remain positive for at least 2 years after apparent
successful treatment [24]. These authors concluded that the
dogma stating that cure equals parasite elimination may need
revision.
Infection by T.b. gambiense is not 100% fatal
Whilst in most patients refusing treatment, infection evolved
‘‘classically’’, i.e. from stage 1 to stage 2 after 2–4 years [10],
eleven patients did not show any appearance of neurological signs.
Apart from subject BONT4, diagnosed in 2007 and confirmed to
still harbour trypanosomes 2 years later, an apparent parasitolog-
ical clearance was observed using microscopy after several years in
the other ten asymptomatic subjects. Parasitological clearance in
these individuals was also suggested by the negative results of the
TBR1/2 PCR, although this seemed a longer process. Based on
the analysis of the serological response, these subjects becoming
apparently aparasitaemic can be divided into two groups.
A first group of seven untreated patients became CATT-P-
negative. Six were still reactive with one or two VATs and one was
negative to all tested VATs. These individuals displayed the same
Table 1. CATT-P and TL results of the 39 treated HAT cases
followed up in 2009 in the Sinfra focus.
Treated HAT P11 Treated HAT P2
CATT-P2 TL3 Number CATT-P TL Number
+ +/+/+ 1 + +/2/2 1
+ 2/2/2 1 2 +/+/+ 1
2 2/2/2 10 2 2/2/2 4
2 +/2/2 3 2 +/2/2 4
2 2/+/2 2 2 2/+/2 6
2 +/+/2 1 2 +/+/2 2
Total = 18 2 +/2/+ 2
2 2/2/+ 1
Total = 21
1HAT patients diagnosed and treated in 1995/1996 as first-stage cases.
2CATT on plasma, considered positive (+) if CATT-P end titres $1/8.
3trypanolysis test, results are given as follows: Litat 1.3/Litat 1.5/Litat 1.6
(+=positive TL).
doi:10.1371/journal.pntd.0001691.t001
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serological profile as observed in the majority of the cured
patients: negative CATT-P results and a progressive loss of
reactivity to LiTat 1.3, 1.5 or 1.6 VATs. Thus, clinical,
parasitological and serological results strongly argue that self-
cure occurred. Scarce and old reports [25,26,27,28] have already
described the existence of spontaneous resolution of infections.
However, these reports have always been interpreted with
caution since at that time microscopic tests were severely
impaired by low sensitivity and no serological tests were available
[7]. The results presented here, combining both follow-up over
5–15 years and the use of the most sensitive and specific
diagnostic tests available, strongly support the fact that sponta-
neous resolution is a possible scenario of T.b. gambiense infection in
humans. As for the cohort of cured patients, however, we cannot
exclude that latent asymptomatic infections persist in the central
nervous system (CNS), since no lumbar puncture was performed
in these subjects who were otherwise healthy and negative to all
parasitological tests performed on blood. Whereas none of the
study subjects reported using traditional medicine, we cannot
objectively exclude that they did use plants with potential
trypanocidal activity [29].
Three untreated patients remained CATT-P-positive and TL-
positive with all three VATs tested. This profile corresponds to the
typical serological profile found in HAT patients in the Ivory Coast
[17] and to the profile observed in patient BONT4, diagnosed in
2007 and confirmed to still harbour trypanosomes in 2009. These
strong long-lasting peripheral serological responses suggest that
these persons are asymptomatic carriers who are able to control
parasitaemia at levels that are undetectable by microscopy and
PCR [30]. Although it is known that antibodies may persist for long
periods, it seems unlikely that maintenance of high CATT
responses associated with positivity to the three VAT for more
than 10 years can occur without some stimulation of the immune
system by T. b. gambiense antigens. Such individuals are probably not
marginal cases as illustrated by the fact that parasitologically non-
confirmed seropositive subjects are frequently encountered during
medical surveys [17,31,32] in different proportions depending on
the disease foci [17]. In Bonon for example, trypanosomes were
demonstrated in less than 50% of the CATT-P and TL-positive
individuals. Likewise, seropositive subjects from the Ivory Coast
and Guinea were shown to maintain their serological profile over
more than 2 years by longitudinal follow-ups [20,30]. Because of
drug toxicity and costs, most parasitologically unconfirmed
seropositive subjects remain untreated. To which extent these
individuals may constitute a human reservoir of parasites contrib-
uting to the maintenance of transmission in HAT foci is presently
unknown and deserves further investigation. It is noteworthy that it
was shown that cattle chronically infected with T.b. brucei [33] and
pigs experimentally infected with T.b. gambiense [34], and where
trypanosomes are almost undetectable in blood, are still infective
for tsetse flies. In this respect, asymptomatic T.b. gambiense infection
is comparable to the frequent asymptomatic infections occurring
with Trypanosoma cruzi and Leishmania sp., two other human
pathogenic members of the Trypanosomatidae [35,36,37]. A differ-
ence however for these parasites, as compared to African
trypanosomes, is that they are encountered in their mammalian
host as intracellular parasites. Although African trypanosomes are
considered to be exclusively extracellular, old and more recent
reports exist on putative intracellular amastigote and trypomasti-
gote forms [38,39]. Whether these forms are viable and/or also
exist in vivo and whether they may be related to the observed long
term seropositivity, remains to be clarified.
Table 2. Results of the follow-up of seven untreated patients in the Sinfra focus.
Year 19991 2004 2009
Patient CATT-P2 T3 PCR CATT-P TL5 T PCR CATT-P TL T PCR
4 + 2 + a4 a a a 2 2/2/2 2 2
5 + 2 + + +/2/+ 2 + 2 +/2/+ 2 2
6 + 2 + a a a a 2 +/2/+ 2 2
7 + 2 + + +/+/+ 2 + + +/+/+ 2 2
12 + + + a a a a + +/+/+ 2 2
13 + + + + +/+/+ 2 + + +/+/+ 2 2
14 + + + + +/2/2 2 + 2 +/+/2 2 2
All patients were positive to the CATT performed on plasma and trypanosomes were detected either in blood or lymph juice when diagnosed between 1995 and 1996.
1Results from Jamonneau et al. (2000).
2CATT on plasma, considered positive (+) (i) in presence of a visible agglutination when performed with 5 ml of plasma (1999 and 2004) and (ii) if CATT-P end titres $1/8
(2009).
3Trypanosome in blood and/or lymph fluid (+=presence, 2= absence).
4absence of the patient.
5trypanolysis test, results are given as follows: Litat 1.3/Litat 1.5/Litat 1.6 (+=positive TL).
doi:10.1371/journal.pntd.0001691.t002
Table 3. Results of the follow-up of four untreated patients in
the Bonon focus in 2009.
Results in 2009
Patient Diagnosed in CATT-P1 T2 TL3 PCR
BONT1 2003 2 2 +/2/+ 2
BONT2 2000 2 2 +/2/+ 2
BONT3 2004 2 2 +/2/+ 2
BONT4 2007 + + +/+/+ +
All patients were positive to the CATT performed on plasma and trypanosomes
were detected either in blood or lymph juice at first diagnosis.
1CATT on plasma, considered positive (+) if CATT-P end titres $1/8.
2Trypanosome in blood and/or lymph juice (+=presence, 2= absence).
3trypanolysis test, results are given as follows: Litat 1.3/Litat 1.5/Litat 1.6
(+=positive TL).
doi:10.1371/journal.pntd.0001691.t003
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Host and parasite factors underlying HAT clinical
diversity remain poorly understood
Altogether, the results presented here strongly suggest that there
are at least two possible alternative natural progressions of HAT in
addition to the ‘‘classic’’ one (Figure 1): (i) progression to an
apparently aparasitaemic and asymptomatic infection associated
with strong long-lasting serological responses and (ii) progression to
an apparently spontaneous resolution of infection (with negative
parasitological and PCR test results) associated with a progressive
drop in antibody titres as observed in treated cases. Interestingly,
similar courses of infection were also observed when T.b. gambiense
isolates from the Ivory Coast were used in murine models [40].
This variety in disease outcome may be associated with the genetic
variability of the parasite and/or the host [6,8,41].
Concerning parasite genetic variability, two studies have shown
that differentT.b. gambiense field isolates from the Ivory Coast exhibit
contrasting infection patterns in a given mice experimental model
and have the capacity to largely influence the host immune response
both in terms of quality and quantity [40,42]. Whether these
differences translate directly to humans, however, remains an open
question. On the contrary, population genetic studies carried out on
trypanosomes from the Ivory Coast and Guinea revealed that T.b.
gambiense genetic diversity is instead linked with geographic and
temporal differentiation processes and did not detect effects on the
severity of disease [32,43,44]. Trypanosome stocks were repeatedly
isolated from several untreated patients included in this study
(patients 12, 13, 14, BONT2 and BONT3). Both isoenzyme analysis
[45] and microsatellite genotyping [46] have shown that these
patients were infected by T.b. gambiense group1 that were similar to
those from the other HAT patients in the same focus. Whole-
genome sequencing is currently underway and will provide an
exhaustive genetic characterisation of these strains.
From the host point of view, only very few studies have directly
assessed the question of genetic susceptibility in humans, in
contrast to the work carried out on inbred strains of mice
displaying differences in susceptibility to trypanosome infections
[47,48] and trypanotolerant cattle [49]. It is, however, noteworthy
that two studies, one of which was performed in the Sinfra focus in
the Ivory Coast and the other in the Democratic Republic of the
Congo, have highlighted associations between cytokine gene
polymorphisms and a variable risk of developing the disease, thus
indicating that the genetic make up of the host may influence
infection outcomes [50,51].
In conclusion, the results presented here, based on the 5- to 15-
year follow-up of untreated patients, definitively demonstrate that
HAT is not 100% fatal. While this study does not allow a precise
evaluation of how frequent self-cure and/or progression to latent
asymptomatic infections are, and whether such phenomenon also
occur in other HAT foci, a disease course such as these were
observed in at least 7 of 53 HAT patients initially refusing
treatment in Ivory Coast. Although most of these 53 patients were
mainly stage-1 patients suffering from mild symptoms and such
infection courses are likely less frequent in stage-2 patients, the fact
that sub-clinical and self-resolving asymptomatic infections appear
to be long-lasting processes argue in favor of the fact that such
individuals may accumulate over time and could thus represent a
large fraction of T.b. gambiense-infected individuals at a given time
in endemic areas. As is widely accepted for rodents and cattle,
trypanotolerance also seems of importance in humans. To what
extent trypanotolerant persons are involved in the transmission
Figure 1. ‘‘Classic’’ and possible alternative natural progressions of HAT. Cpl = CATT on plasma, considered positive (Cpl+) if end titres$1/
8 TL = Trypanolysis test, considered positive (TL+) if positive to at least one variant P = Parasitological investigations in blood and/or lymph fluid
(P+=presence of trypanosome).
doi:10.1371/journal.pntd.0001691.g001
Self-Cure and Latent Infections in HAT
www.plosntds.org 5 June 2012 | Volume 6 | Issue 6 | e1691
cycle and the respective role of host and parasite factors deserves
further investigation.
From our point of view, recognising that trypanotolerance exists
in humans is a major step forward for future research in the field of
HAT. It has implications both (i) at the intervention level, since
these data suggest that latent infections (undetectable by the
parasitological tests used in the field) may last for years and thus
participate in the maintenance of transmission in endemic areas
despite the control measures taken and (ii) at the scientific level,
since the trypanotolerant phenotype in humans opens the way to
identifying human-specific defence and immune mechanisms
involved in the control of T.b. gambiense infection and thus new
candidate therapeutic or prophylactic targets.
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